Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Anemia (1)
- Anger (1)
- Anorexia (1)
- Antibody (1)
- Antiviral activity (1)
-
- Antiviral therapy (1)
- Arthralgia (1)
- Attention deficit disorder (1)
- Clinical trial (1)
- Depression (1)
- Dose response (1)
- Drug contraindication (1)
- Drug dose escalation (1)
- Drug dose reduction (1)
- Drug efficacy (1)
- Drug fever (1)
- Drug induced headache (1)
- Drug safety (1)
- Drug withdrawal (1)
- Fatigue (1)
- Genotype (1)
- Hemolytic anemia (1)
- Hepatitis C (1)
- Highly active antiretroviral therapy (1)
- Human (1)
- Human immunodeficiency virus infected patient (1)
- Human immunodeficiency virus infection (1)
Articles 1 - 2 of 2
Full-Text Articles in Hepatology
The Use Of Infliximab In Older Inflammatory Bowel Disease Patients, Stephanie M. Moleski, Christina C. Lindenmeyer, Patricia L. Kozuch
The Use Of Infliximab In Older Inflammatory Bowel Disease Patients, Stephanie M. Moleski, Christina C. Lindenmeyer, Patricia L. Kozuch
Department of Medicine Faculty Papers
Limited data suggest anti-tumor necrosis factor (TNF) antibodies have equal efficacy but higher morbidity and mortality in older compared to younger inflammatory bowel disease (IBD) patients(1).
Pegylated Interferon 2a And 2b In Combination With Ribavirin For The Treatment Of Chronic Hepatitis C In Hiv Infected Patients., Ravinder Dhillon, Simona Rossi, Steven K Herrine
Pegylated Interferon 2a And 2b In Combination With Ribavirin For The Treatment Of Chronic Hepatitis C In Hiv Infected Patients., Ravinder Dhillon, Simona Rossi, Steven K Herrine
Department of Medicine Faculty Papers
Coinfection with hepatitis C virus (HCV) and HIV is an increasingly recognized clinical dilemma, particularly since the advent of highly active antiretroviral therapy. Several studies of this population have demonstrated both more rapid progression of liver disease and poorer overall prognosis compared to HCV monoinfected patients. Consensus guidelines, based primarily on the results of 4 major randomized trials, recommend treatment with peginterferon and ribavirin for 48 weeks in coinfected patients. However, this current standard of care is associated with lower response rates to therapy than those seen in monoinfected patients. Important predictors of response include HCV genotype, pretreatment HCV RNA …